Literature DB >> 21767998

Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth.

Aleksandra Lisowska1, Andrzej Pogorzelski, Grzegorz Oracz, Katarzyna Siuda, Wojciech Skorupa, Marta Rachel, Szczepan Cofta, Tomasz Piorunek, Jarosław Walkowiak.   

Abstract

BACKGROUND: The aim of the present study was to assess the influence of antibiotic therapy on fat assimilation in cystic fibrosis (CF) patients with small intestine bacterial overgrowth (SIBO).
MATERIALS AND METHODS: Twenty six pancreatic insufficient CF patients with bronchopulmonary exacerbation and diagnosed SIBO (positive hydrogen-methane breath test) entered the study. (13)C mixed triglyceride breath test was performed before and after antibiotic therapy. Sixteen subjects were treated intravenously (ceftazidime and amikacin), ten patients orally (ciprofloxacin).
RESULTS: Cumulative percentage dose recovery changed significantly in the subgroup receiving antibiotics orally [median (mean±SEM): 3.6% (4.5±1.3%) vs. 7.2 (6.9±1.6%); p=0.019]. In the subgroup with intravenous drug administration, the tendency towards improvement was noted [2.7 (4.3±1.5%) vs. 5.2 (5.7±0.8%); p=0.109].
CONCLUSIONS: Antibiotic therapy applied in CF patients with SIBO in the course of pulmonary exacerbation results in a significant improvement of fat digestion and absorption.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767998     DOI: 10.1016/j.jcf.2011.06.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

Review 1.  Beyond pancreatic insufficiency and liver disease in cystic fibrosis.

Authors:  Stephanie Demeyer; Kris De Boeck; Peter Witters; Katrien Cosaert
Journal:  Eur J Pediatr       Date:  2016-04-07       Impact factor: 3.183

2.  The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Authors:  Manuele Furnari; Alessandra De Alessandri; Federico Cresta; Maria Haupt; Marta Bassi; Angela Calvi; Riccardo Haupt; Giorgia Bodini; Iftikhar Ahmed; Francesca Bagnasco; Edoardo Giovanni Giannini; Rosaria Casciaro
Journal:  J Gastroenterol       Date:  2018-09-19       Impact factor: 7.527

Review 3.  Luminal Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Samuel J Burton; Christine Hachem; James M Abraham
Journal:  Curr Gastroenterol Rep       Date:  2021-03-23

4.  Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis.

Authors:  Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Krzysztof Dziedzic; Aleksandra Lisowska; Szymon Kurek; Joanna Goździk-Spychalska; Victoria Kononets; Dagmara Woźniak; Edyta Mądry; Jarosław Walkowiak
Journal:  Biomolecules       Date:  2021-02-19

Review 5.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

Review 6.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.